Neuromyelitis optica spectrum disorders in children and adolescents

Neurology

Volumn 87, Issue 9, 2016, Pages S59-S66

  Tenembaum, Silvia ^a   Chitnis, Tanuja ^b   Nakashima, Ichiro ^c   Collongues, Nicolas ^d   McKeon, Andrew ^e   Levy, Michael ^f   Rostasy, Kevin ^g  

^a Hospital de Pediatria SAMIC Prof Dr Juan P Garrahan   (Argentina)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e MAYO CLINIC   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; AUTOANTIBODY; AZATHIOPRINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; RITUXIMAB;

ADOLESCENT DISEASE; ARTICLE; AUTOIMMUNE DISEASE; CHILDHOOD DISEASE; DEMOGRAPHY; HUMAN; IMMUNOPATHOGENESIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHENOTYPE; PLASMA EXCHANGE; PREVALENCE; PRIORITY JOURNAL; RELAPSE; ADOLESCENT; BLOOD; CHILD; NEUROMYELITIS OPTICA; PATHOLOGY; SPINAL CORD;

ADOLESCENT; AUTOANTIBODIES; CHILD; HUMANS; NEUROIMAGING; NEUROMYELITIS OPTICA; SPINAL CORD;

EID: 85003550737     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002824     Document Type: Article

References (40)

1. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
2. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202:473-477.
3. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6: 805-815.
4. McKeon A, Lennon VA, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008;71:93-100.
5. Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler 2015;21:845-853.
6. Cabrera-Gomez JA, Kurtzke JF, González-Quevedo A, Lara-Rodríguez R. An epidemiological study of neuromyelitis optica in Cuba. J Neurol 2009;256:35-44.
7. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114.
8. Banwell B, Bar-Or A, Arnold DL, et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: A prospective national cohort study. Lancet Neurol 2011;10:436-445.
9. Ketelslegers IA, Catsman-Berrevoets CE, Neuteboom RF, et al. Incidence of acquired demyelinating syndromes of the CNS in Dutch children: A nationwide study. J Neurol 2012;259:1929-1935.
10. Langer-Gould A, Zhang JL, Chung J, et al. Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. Neurology 2011;77:1143-1148.
11. Absoud M, Cummins C, Desai N, et al. Childhood optic neuritis clinical features and outcome. Arch Dis Child 2011;96:860-862.
12. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
13. Wingerchuk D, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-189.
14. Verhey LH, Branson HM, Makhija M, et al. Magnetic resonance imaging features of the spinal cord in pediatric multiple sclerosis: A preliminary study. Neuroradiology 2010;52:1153-1162.
15. Tenembaum S, Chitnis T, Ness J, et al. Acute disseminated encephalomyelitis. Neurology 2007;68:S23-S36.
16. Banwell B, Tenembaum S, Lennon VA, et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008;70:344-352.
17. Absoud M, Lim MJ, Appleton R, et al. Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features. J Neurol Neurosurg Psychiatry 2015;86:470-472.
18. Collongues N, Marignier R, Zephir H, et al. Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology 2010;75:1084-1088.
19. Kremer L, Mealy M, Jacob A, et al. Brainstem manifestations in neuromyelitis optica: A multicenter study of 258 patients. Mult Scler 2014;20:843-847.
20. Pena JA, Ravelo ME, Mora-La Cruz E, Montiel-Nava C. NMO in pediatric patients: brain involvement and clinical expression. Arq Neuropsiquiatr 2011;69:34-38.
21. Longoni G, Bigi S, Branson HM, et al. Multicystic demyelinating myelopathy: widening spectrum of pediatric aquaporin-4 autoimmunity. Neurology 2014;82: 902-903.
22. Bukhari W, Barnett MH, Prain K, Broadley SA. Molecular pathogenesis of neuromyelitis optica. Int J Mol Sci 2012;13:12970-12993.
23. Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 2012;1:180-187.
24. Fryer JP, Lennon VA, Pittock SJ, et al. AQP4 autoantibody assay performance in clinical laboratory service. Neurol Neuroimmunol Neuroinflamm 2014;1:e11.
25. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665-671.
26. Fragoso YD, Ferreira ML, Oliveira EML, et al. Neuromyelitis optica with onset in childhood and adolescence. Ped Neurol 2014;50:66-68.
27. Rostasy K, Mader S, Schanda K, et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol 2012;69:752-756.
28. Rostasy K, Reindl M. Role of autoantibodies in acquired inflammatory demyelinating diseases of the central nervous system in children. Neuropediatrics 2013;44:297-301.
29. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibodypositive NMO spectrum disorders. Neurology 2014;82: 474-481.
30. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelinoligodendrocyte glycoprotein antibodies: A comparative study. JAMA Neurol 2014;71:276-283.
31. Rostasy K, Mader S, Hennes EM. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 2013;19:1052-1059.
32. McKeon A, Lennon VA, Jacob A, et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 2009;39:87-90.
33. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica study group (NEMOS). J Neurol 2014;261:1-16.
34. Tenembaum S. Treatment of multiple sclerosis and neuromyelitis optica in children and adolescents. Clin Neurol Neurosurg 2013;115(suppl 1):S21-S29.
35. Ratelade J, Smith AJ, Verkman AS. Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica. Exp Neurol 2014;255: 145-153.
36. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011;77:659-666.
37. Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability, and retention rate of azathioprine in 103 acquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: A multicentre retrospective observational study from the UK. Mult Scler 2014;20: 1533-1540.
38. Mahmood NA, Silver K, Onel K. Efficacy and safety of rituximab in pediatric neuromyelitis optica. J Child Neurol 2011;26:244-247.
39. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009;66: 1128-1133.
40. Kageyama T, Komori M, Miyamoto K, et al. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol 2013;260: 627-634.